Abstract
Abstract BACKGROUND AND AIMS Prior results demonstrated preliminary in peritoneal dialysis (PD) patients that mesothelial cells are able to undergo mesothelial to mesenchymal transition (MMT) by differential genomic reprogramming, correlating with local damage of the peritoneum and a final ultrafiltration failure [1]. Therefore, our main goal is to find biomarkers with prediction and diagnosis value of all PD-induced MMT changes and CVD outcomes in PD effluents, biopsies or plasma from a longitudinal retrospective study of a European patient cohort of CKD, PD and HD, correlating them with cardiovascular disease (CVD), systemic inflammation, patient outcomes and animal models along with the IMPROVE-PD consortium. METHOD Analysis of EU biobanks: interrelation of MMT and CVD markers by qRT-PCR, immunohistochemistry, 3D-transwell models, citometry (Magpix) and echocardiography. Statistical analysis and machine learning (MA): correlograms, PCA modelling, K-means clustering, decision trees. RESULTS CONCLUSION Despite the rising awareness of the need for the improvement of the PD-MMT process, patients still carry a heavy burden of CVD and low survival rates of 5 years. IMPROVE-PD intends to combat them from different clinical and research fronts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.